Wow, Anika's stock tanked post-Q1 2025 earnings due to a 10% revenue drop, lower OEM pricing, manufacturing issues, and reduced guidance.
Anika Therapeutics' stock tanked after the Q1 2025 earnings call due to several negative financial and operational updates:
Revenue Decline: Total revenue fell 10% year-over-year to $26.2 million, driven by a 23% drop in the OEM channel, primarily due to lower pricing for Monovisc and Orthovisc sold by J&J MedTech.
Gross Margin Drop: Gross margin decreased to 56% from 65% in Q1 2024, impacted by lower high-margin J&J sales and manufacturing yield ...
The Orthopedics Industry 
